Pelthos Q3 Call: Zelsuvmi Revenue $15.2M, Extra $10M Drawn on Horizon Loan
PTHS is trading near its 52-week low of $7.785 (3.1% above the low) on elevated volume (2.6× avg).
Summary
Pelthos' Q3 call paired $15.2 million of Zelsuvmi revenue with a fresh $10 million draw on its Horizon term loan and $17.7 million of cash, while management argued the commercial base can fund the Castle Creek deal with limited dilution.
Key Events · Earnings and Guidance · PTHS
-
Q3 Zelsuvmi Revenue $15.2M, Up 114% YoY
Net product revenue was $15.2 million versus $15.4 million in Q2 2026, with prescriptions up 4% sequentially to 12,384 and unique prescribers up to 4,942.
-
Extra $10M Drawn on Horizon Facility
Pelthos amended its $50 million Horizon term loan on October 30, 2026 and borrowed an additional $10 million; another $10 million is available before December 31, 2027 if trailing 12-month net revenue reaches at least $70 million.
-
Balance Sheet: $17.7M Cash, $13.4M Receivables
Working capital was $24.6 million at September 30, 2026, down from $31.4 million at the end of Q2 2026.
-
Gross-to-Net Rises to 31.5% on PBM Deal
Q3 gross-to-net was 31.5% versus 29.6% in Q2 after a new PBM contract effective October 1, 2026 opened about 24 million lives without prior authorization; management guides to the mid-30s going forward.
Analysis · PTHS · Life Sciences
The transcript supplies hard numbers that the morning's 8-K and 10-Q did not spell out in narrative form: an additional $10 million borrowed on October 30 under the amended Horizon facility, $17.7 million of cash against $13.4 million of receivables, and gross-to-net guided to the mid-30s from 31.5%. Zelsuvmi revenue of $15.2 million was roughly flat sequentially ($15.4 million in Q2) because management traded gross-to-net for a new PBM contract covering about 24 million lives without prior authorization — a deliberate investment in 2027 growth rather than a demand problem. Against a stock near its 52-week low of $7.79, the call is management's case that a cash-generating commercial base can fund the Castle Creek gene-therapy pivot with less dilution; the S-4 remains the next hard disclosure point.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PTHS was trading at $8.03 on NYSE in the Life Sciences sector, with a market capitalization of approximately $31.6M. The 52-week trading range was $7.79 to $37.40. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.